Patient centered care for individuals with advanced liver disease
Patient centered care for individuals with advanced liver disease
批准号:
10186511
负责人:
FASIHA KANWAL
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2022-04-30
关键词:
AffectAgeAlcohol consumptionAscitesCaregiversCaringCategoriesChildChronic DiseaseClinicalClinical DataCollaborationsComplementDataDiagnosisDiseaseDisease OutcomeDisease ProgressionDrug usageElementsEmergency department visitEncephalopathiesEnrollmentEnsureFaceFoundationsFutureGenderGoalsHealthHealthcareHomelessnessHospitalizationIndividualInterventionInterviewKnowledgeLifeLiverLiver diseasesLongevityMalignant NeoplasmsMalignant neoplasm of liverMedicalMental HealthMethodsModelingMorbidity - disease rateNeeds AssessmentOutcomePalliative CareParticipantPatient CarePatient PreferencesPatient-Centered CarePatient-Focused OutcomesPatientsPerceptionPersonal SatisfactionPovertyPrognosisRaceResourcesRetrospective cohort studyRiskRisk EstimateRoleSamplingSeveritiesSeverity of illnessShapesSupportive careSymptomsTimeTransplantationVeteransWaiting Listsalcohol use disorderclinical carecohortcomorbiditydata warehousedesigndirect patient careexpectationexperiencehigh riskillness perceptionsimprovedindexinginnovationliver transplantationmortalitymortality riskoperationpalliativepatient orientedpatient stratificationphysical conditioningpreferenceprognosticprognostic modelpsychosocialrisk prediction modelrisk stratificationsociodemographicstreatment planning
中文摘要
背景:确保患有严重疾病的退伍军人获得以患者为中心的护理是一个基本目标
的VA。晚期肝病(AdvLD)是一种严重的疾病,不成比例地影响退伍军人,
其特征是健康状况下降、症状增加和频繁住院。近期以患者为中心
在其他情况下的护理模式,如癌症,促进了支持性和姑息性的早期整合,
治疗护理。这些模型可以提高质量甚至寿命。AdvLD的综合护理至关重要
因为它可以减少并发症,保持功能和健康,甚至可以延长寿命。
目的:由于特定的原因,以患者为中心的综合AdvLD护理模型开发缓慢。
知识差距。首先,缺乏对疾病严重程度和进展的准确和完整的理解。
其次,没有研究描述退伍军人的经历和对他们的AdvLD严重程度的理解,或者
在整个疾病严重程度范围内的护理目标。第三,我们对临床医生的经验知之甚少,
期望和感知障碍提供AdvLD护理。我们建议的研究,在密切
与AdvLD患者,护理人员,临床医生和临床运营合作伙伴的合作,将使用多-
方法的方法,以填补这些差距,所以至关重要的发展综合护理的AdvLD。我们的具体目标是:
(1)开发风险预测模型,将患者分为关键AdvLD结局的不同风险组;
(2)描述患者和护理人员的经验和AdvLD护理的目标,包括对疾病的看法
严重程度、对所需风险信息的数量和类型的偏好以及预期的健康结果目标;
以及(3)确定临床医生对以患者为中心的AdvLD护理的机会和障碍的看法。
方法:为了实现目标1,我们将对在2011年12月至2013年12月期间观察到的患有AdvLD的退伍军人进行一项全国回顾性队列研究。
2011年至2015年。我们将使用VA Corporate Data中预先存在的管理和临床数据
将联合收割机肝脏严重程度指数与社会人口统计学(年龄、性别、无家可归)、临床
(身心健康并发症,酒精使用)和医疗保健资源使用(住院,
急诊室就诊)因素,以提供三种以患者为中心的结局的风险类别估计:
发生AdvLD并发症、需要AdvLD相关住院治疗和总体死亡率。实现
目标2,我们将对60名AdvLD患者和30名护理人员进行深入的定性访谈,
3个不同的VA设施。参与者将按风险分层(例如,低、中或高风险
AdvLD特异性并发症的死亡率)。为了实现目标3,我们将进行深入的定性访谈
30名临床医生参与了AdvLD患者的直接护理。采访将考察他们在以下方面的经历:
沟通风险和制定治疗计划;他们和他们的病人在治疗中的角色的看法
计划;以及提供与患者健康结果目标一致的护理的障碍和促进因素。
意义:这些目标将共同产生对当前临床护理有直接影响的产品,
晚期肝病以及为发展以患者为中心的综合性
确保与患者偏好一致的及时支持性和姑息治疗的AdvLD治疗方法
以及VA中提供的当代AdvLD护理背景下的健康结局目标。
英文摘要
Background: Ensuring that Veterans with serious illness receive patient-centered care is a fundamental goal
of VA. Advanced liver disease (AdvLD) is a serious illness that disproportionately affects Veterans and is
characterized by declining health, increasing symptoms and frequent hospitalizations. Recent patient-centered
models of care in other conditions, like cancer, have promoted early integration of supportive and palliative with
curative care. These models can improve quality and even length of life. Integrated care in AdvLD is essential
because it can reduce complications, maintain both function and well-being, and may even prolong life.
Objectives: Patient-centered models of integrated AdvLD care have been slow to develop due to specific
knowledge gaps. First, precise and complete understanding of disease severity and progression is lacking.
Second, no studies exist that characterize Veterans' experiences and understanding of their AdvLD severity, or
goals of care across the spectrum of disease severity. Third, little is known about clinicians' experiences,
expectations, and perceived barriers to delivering AdvLD care. Our proposed study, conducted in close
collaboration with AdvLD patients, caregivers, clinicians and clinical operations partners, will use a multi-
method approach to fill these gaps so crucial to developing integrated care for AdvLD. Our specific aims are:
(1) to develop risk prediction models to stratify patients into groups at different risks for key AdvLD outcomes;
(2) to describe patient and caregiver experiences and goals of AdvLD care, including perceptions of illness
severity, preferences for the amount and type of risk information desired, and expected health outcome goals;
and (3) to identify clinicians' perceptions of opportunities and barriers to patient-centered AdvLD care.
Methods: For Aim 1, we will conduct a national retrospective cohort study of Veterans with AdvLD seen in the
VA between 2011 and 2015. We will use pre-existing administrative and clinical data in VA Corporate Data
Warehouse to combine liver severity indices with sociodemographic (age, gender, homelessness), clinical
(physical and mental health comorbidity, alcohol use), and healthcare resource use (hospitalization,
emergency room visits) factors to provide risk category estimates for three patient-centered outcomes: risk of
developing AdvLD complications, requiring AdvLD related hospitalizations, and overall mortality. To achieve
Aim 2, we will conduct in-depth qualitative interviews with 60 patients who have AdvLD, and 30 caregivers, at
3 diverse VA facilities. Participants will be stratified by risk strata (e.g., low, intermediate or high risk of
mortality from AdvLD-specific complications). To achieve Aim 3, we will conduct in-depth qualitative interviews
with 30 clinicians involved in direct care of patients with AdvLD. Interviews will examine their experiences in
communicating risk and making treatment plans; perceptions of their and their patients' roles in treatment
planning; and barriers to and facilitators of providing care aligned with patients' health outcome goals.
Significance: Together, these aims will yield products that have direct impact on current clinical care of
advanced liver disease as well as provide the foundation for developing a patient-centered, integrated
approach to AdvLD care that ensures timely supportive and palliative care consistent with patients' preferences
and health outcome goals within the context of contemporary AdvLD care as provided in the VA.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.cgh.2019.07.043
发表时间:
2020-05
期刊:
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
影响因子:
12.6
作者:
[Naik, Aanand D., Arney, Jennifer, Clark, Jack A., Martin, Lindsey A., Paragraph, Anne M. Walling, Stevenson, Autumn, Smith, Donna, Asch, Steven M., Kanwal, Fasiha]
通讯作者:
Kanwal, Fasiha
DOI:
10.1016/j.socscimed.2022.115113
发表时间:
2022-07
期刊:
SOCIAL SCIENCE & MEDICINE
影响因子:
5.4
作者:
[Gray, Caroline, Arney, Jennifer, Clark, Jack A., Walling, Anne M., Kanwal, Fasiha, Naik, Aanand D.]
通讯作者:
Naik, Aanand D.
DOI:
10.1371/journal.pone.0263874
发表时间:
2022
期刊:
PloS one
影响因子:
3.7
作者:
[Arney J, Gray C, Clark JA, Smith D, Swank A, Matlock DD, Melcher J, Kanwal F, Naik AD]
通讯作者:
Naik AD
Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality.
对简单的机器学习模型的开发,验证和评估,以预测肝硬化死亡率。
DOI:
10.1001/jamanetworkopen.2020.23780
发表时间:
2020-11-02
期刊:
JAMA network open
影响因子:
13.8
作者:
[Kanwal F, Taylor TJ, Kramer JR, Cao Y, Smith D, Gifford AL, El-Serag HB, Naik AD, Asch SM]
通讯作者:
Asch SM
Chemoprevention of HCC related to MAFLD
-
批准号:10410751
-
项目类别:
-
资助金额:$21.22万
-
财政年份:2022
-
负责人:FASIHA KANWAL
-
依托单位:
Chemoprevention of HCC related to MAFLD
-
批准号:10657423
-
项目类别:
-
资助金额:$19.68万
-
财政年份:2022
-
负责人:FASIHA KANWAL
-
依托单位:
Clinical Validation Center for Hepatocellular Carcinoma
-
批准号:10676320
-
项目类别:
-
资助金额:$104.14万
-
财政年份:2022
-
负责人:FASIHA KANWAL
-
依托单位:
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes
-
批准号:10374004
-
项目类别:
-
资助金额:$54.58万
-
财政年份:2021
-
负责人:FASIHA KANWAL
-
依托单位:
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes
-
批准号:10606494
-
项目类别:
-
资助金额:$59.67万
-
财政年份:2021
-
负责人:FASIHA KANWAL
-
依托单位:
Patient centered care for individuals with advanced liver disease
-
批准号:9701020
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:FASIHA KANWAL
-
依托单位:
Risk Stratification for and Early Detection of Liver Cancer
-
批准号:10473708
-
项目类别:
-
资助金额:$64.75万
-
财政年份:2018
-
负责人:FASIHA KANWAL
-
依托单位:
Risk Stratification for and Early Detection of Liver Cancer
-
批准号:10239079
-
项目类别:
-
资助金额:$68.83万
-
财政年份:2018
-
负责人:FASIHA KANWAL
-
依托单位:
Care for Women Veterans with Hepatitis C Virus Infection
-
批准号:8596038
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:FASIHA KANWAL
-
依托单位:
Study Design & Clinical Research Core
-
批准号:10377550
-
项目类别:
-
资助金额:$16.43万
-
财政年份:2001
-
负责人:FASIHA KANWAL
-
依托单位:
Clinical Research & Study Design Core
-
批准号:10576215
-
项目类别:
-
资助金额:$17.02万
-
财政年份:2001
-
负责人:FASIHA KANWAL
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: